

Contact

www.linkedin.com/in/mark-blumenkranz-20b31933 (LinkedIn)

Mark Blumenkranz

Managing Director Lagunita Biosciences, Chairman and CEO
Kedalion Therapeutics
Menlo Park

Summary

Mark S. Blumenkranz, M.D., MMS, is a co-founder and the Chairman and CEO of Kedalion Therapeutics a clinical stage ophthalmic pharmaceutical company. He is also the Managing Director of Lagunita Biosciences an early stage healthcare investment company and incubator in Menlo Park CA and HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University where he is the Founder and Co-Director of the Ophthalmic Innovation Program. He served as the Chairman of the Department of Ophthalmology from 1997 until 2015 and played a leading role in the planning, fundraising and construction of the Byers Eye Institute at Stanford. He is a past President of the American University Professors of Ophthalmology (AUPO), the Retina Society and the Macula Society and is a Fellow Emeritus of the Corporation of Brown University where he chaired the Medical School Committee (2002-2019). He is a member of the steering committee of the National Eye Institute's Audacious Goals Initiative, and was a member of the Board of Trustees of the Jackson Laboratory from 2017 to 2020.

He was a director and Head of the SAB at Oculex Pharmaceuticals where he designed the pivotal trial for Ozurdex, prior to its acquisition by Allergan in 2003. He was a founder and director of Peak Surgical, that was acquired by Medtronic in 2011 and Optimedica, where he co-wrote the IP for the PASCAL and Catalys lasers and which was acquired by AMO in 2013 and is now part of Johnson and Johnson. He co-founded and served as Chairman of the Board of Adverum Biotechnologies (ADVM:NASDAQ) a publicly traded ophthalmic gene therapy from 2006 until October 2016 and was a co-founder and director of Oculeve, a dry eye company which was acquired by Allergan in 2015. He is a co-founder and serves as a director of Verana Health and is a member of the board of Directors of BVI Visitec and One Medical (ONEM:NASDAQ).

Experience

Byers Eye Institute at Stanford University

HJ Smead Professor Emeritus, Director of the Ophthalmic Innovation Program

September 1992 - Present (29 years 5 months)

Chairman of the Department of Ophthalmology at Stanford from 1997 until 2015 and a practicing vitreoretinal specialist with interests in entrepreneurship and technology transfer in the areas of biopharmaceuticals and medical devices. He is a co-founder and past Chairman of the Board of Adverum Biotechnologies (NASDAQ:AAVL) and a founder and managing partner of Lagunita BioSciences an early stage investment company and life sciences accelerator headquartered in Menlo Park California.

Education

Brown University

AB, MMS, MD, Biochemical Pharmacology, Medicine · (1968 - 1975)